Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Workman

Showing results (11-20 of 268) with videos related to

Pageof 27
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1992
Infusional anthracyclines: is slower better? If so, why?P Workman
Current Cancer Drug Targets|August 22, 2002
New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challengesP Workman
Cancer Surveys|January 1, 1993
Pharmacokinetics and cancer: successes, failures and future prospectsP Workman
European Journal of Cancer & Clinical Oncology|December 1, 1987
TCNU: a ray of hope for designer nitrosoureas?P Workman
Current Opinion in Oncology|December 1, 1989
New drugs and novel agentsP Workman
British Journal of Cancer|September 1, 1979
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in miceP Workman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2002
The impact of genomic and proteomic technologies on the development of new cancer drugsP Workman
Biochemical Society Transactions|March 30, 2004
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatmentP Workman
Human & Experimental Toxicology|February 1, 1995
To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?P Workman
The Lancet. Oncology|March 22, 2002
Paul Workman--at the cutting edge of drug discovery (interview by Dorothy Bonn)P Workman
Pageof 27

Showing results (11-20 of 268) with videos related to

Sort By:
Pageof 27
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1992
Infusional anthracyclines: is slower better? If so, why?P Workman
Current Cancer Drug Targets|August 22, 2002
New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challengesP Workman
Cancer Surveys|January 1, 1993
Pharmacokinetics and cancer: successes, failures and future prospectsP Workman
European Journal of Cancer & Clinical Oncology|December 1, 1987
TCNU: a ray of hope for designer nitrosoureas?P Workman
Current Opinion in Oncology|December 1, 1989
New drugs and novel agentsP Workman
British Journal of Cancer|September 1, 1979
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in miceP Workman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2002
The impact of genomic and proteomic technologies on the development of new cancer drugsP Workman
Biochemical Society Transactions|March 30, 2004
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatmentP Workman
Human & Experimental Toxicology|February 1, 1995
To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?P Workman
The Lancet. Oncology|March 22, 2002
Paul Workman--at the cutting edge of drug discovery (interview by Dorothy Bonn)P Workman
Pageof 27